Aspirin Resistance in Systemic Lupus Erythematosus (SLE) - NCT00731302-37232 (Clinical Trial 235411)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy235411.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Nashville |
|
State:
|
|
TN |
| Zip Code: |
|
37232 |
| Conditions: |
|
Systemic Lupus Erythematosus |
| Purpose: |
|
This study examine whether patients with lupus respond to aspirin , and if not, if that is
related to inflammation. We examine the ability of aspirin to inhibit the production of
thromboxane in patients with lupus and controls and see if aspirin insensitive thromboxane
production is inhibited by meloxicam.
|
| Study summary: |
|
Premature cardiovascular disease is a major cause of mortality in patients with systemic
lupus erythematosus (SLE) with the risk of myocardial infarction increased up to 50-fold. In
addition to defining the mechanisms for accelerated atherosclerosis it is important to
define the effects of drugs used to reduce cardiovascular risk in high-risk patients. Low
dose aspirin, by inhibiting thromboxane A2 biosynthesis, has profound antiplatelet effects,
but some patients have impaired thromboxane suppression - a phenomenon termed aspirin
resistance. An explanation is that aspirin-independent thromboxane synthesis may occur
through enhanced COX-2 activity, as would occur in an inflammatory condition such as lupus.
However, little is known about the effects of low-dose aspirin in SLE. Thus, we propose to
test the following hypothesis: 1) that aspirin insensitive thromboxane biosynthesis is
increased in patients with lupus and is mediated by increased COX-2 activity. |
| Criteria: |
|
Inclusion Criteria:
- Written Informed consent.
- Age >18 yrs.
- SLE meeting ACR criteria {Tan, Cohen, et al. 1982 1482 /id} for at least 6
months.(SLE group)
- Stable disease activity as evidenced by no change in immunosuppressive therapy in the
past 1 month.
- If female of childbearing potential must use an effective method of birth control
Exclusion criteria.
- Renal disease (creatinine >1.5 mg/dL, dialysis, 2+ or more proteinuria)
- Previous or current history of peptic ulcer disease or gastrointestinal bleed.
- Previous or current thromboembolic or ischemic cardiovascular event (stroke,
myocardial infarction, angina) - can do aspirin part of study.
- Currently taking an anticoagulant or antiplatelet agent (besides aspirin).
- Thrombocytopenia (platelet count <135,000)
- Pregnancy
- Allergy to aspirin, NSAIDs
- NSAIDs in the previous week |
|
|
|
| Study is available at: |
|
Vanderbilt University Medical School
Nashville, TN 37232
United States
Primary Contact:
Charles M Stein
Email: michael.stein@vanderbilt.edu
Phone: 615-936-3420
Secondary Contact:
Charles M Stein
Email: michael.stein@vanderbilt.edu
Phone: 615 936 3420 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|